Journal
INTEGRATIVE CANCER THERAPIES
Volume 20, Issue -, Pages -Publisher
SAGE PUBLICATIONS INC
DOI: 10.1177/15347354211021920
Keywords
Zinc Oxide-Caffeic Acid Nanoparticles (ZnO-CA NPs); antitumor; radiosensitizing effect; solid Ehrlich carcinoma; female mice
Categories
Ask authors/readers for more resources
ZnO-CA NPs demonstrate anticancer activity both in vitro and in vivo, which is enhanced by combination with gamma-irradiation.
This study aimed to evaluate the anticancer and radio-sensitizing efficacy of Zinc Oxide-Caffeic Acid Nanoparticles (ZnO-CA NPs). ZnO-CA NPs were formulated by the conjugation of Zinc Oxide nanoparticles (ZnO NPs) with caffeic acid (CA) that were characterized by Fourier Transform Infrared Spectra (FT-IR), X-ray Diffractometer (XRD), and Transmission Electron Microscopy (TEM). In vitro anticancer potential of ZnO-CA NPs was evaluated by assessing cell viability in the human breast (MCF-7) and hepatocellular (HepG2) carcinoma cell lines. In vivo anticancer and radio-sensitizing effects of ZnO-CA NPs in solid Ehrlich carcinoma-bearing mice (EC mice) were also assessed. Treatment of EC mice with ZnO-CA NPs resulted in a considerable decline in tumor size and weight, down-regulation of B-cell lymphoma 2 (BCL2) and nuclear factor kappa B (NF-kappa B) gene expressions, decreased vascular cell adhesion molecule 1 (VCAM-1) level, downregulation of phosphorylated-extracellular-regulated kinase 1 and 2 (p-ERK1/2) protein expression, DNA fragmentation and a recognizable peak at sub-G(0)/G(1) indicating dead cells' population in cancer tissues. Combined treatment of ZnO-CA NPs with gamma-irradiation improved these effects. In conclusion: ZnO-CA NPs exhibit in-vitro as well as in-vivo antitumor activity, which is augmented by exposure of mice to gamma-irradiation. Further explorations are warranted previous to clinical application of ZnO-CA NPs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available